CA2136213A1 - Tissus de taxus cultives en tant que source de taxol, taxanes connexes et autres composes antitumoraux et antiviraux - Google Patents

Tissus de taxus cultives en tant que source de taxol, taxanes connexes et autres composes antitumoraux et antiviraux

Info

Publication number
CA2136213A1
CA2136213A1 CA002136213A CA2136213A CA2136213A1 CA 2136213 A1 CA2136213 A1 CA 2136213A1 CA 002136213 A CA002136213 A CA 002136213A CA 2136213 A CA2136213 A CA 2136213A CA 2136213 A1 CA2136213 A1 CA 2136213A1
Authority
CA
Canada
Prior art keywords
taxol
taxus
roots
cell line
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002136213A
Other languages
English (en)
Inventor
Richard N. Arteca
Enaksha Wickremesinhe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2136213A1 publication Critical patent/CA2136213A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
CA002136213A 1992-05-21 1993-05-11 Tissus de taxus cultives en tant que source de taxol, taxanes connexes et autres composes antitumoraux et antiviraux Abandoned CA2136213A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88661992A 1992-05-21 1992-05-21
US07/886,619 1992-05-21
PCT/US1993/004424 WO1993023555A1 (fr) 1992-05-21 1993-05-11 Tissus de taxus mis en culture utilise comme source de taxol, taxanes et autres nouveaux composes antitumoraux/antiviraux apparantes

Publications (1)

Publication Number Publication Date
CA2136213A1 true CA2136213A1 (fr) 1993-11-25

Family

ID=25389395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002136213A Abandoned CA2136213A1 (fr) 1992-05-21 1993-05-11 Tissus de taxus cultives en tant que source de taxol, taxanes connexes et autres composes antitumoraux et antiviraux

Country Status (5)

Country Link
EP (1) EP0642586A4 (fr)
JP (1) JPH08500973A (fr)
AU (1) AU4242993A (fr)
CA (1) CA2136213A1 (fr)
WO (1) WO1993023555A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264951B1 (en) 1992-02-20 2007-09-04 Phyton, Inc. Enhanced production of taxol and taxanes by cell cultures of Taxus species
CA2434692A1 (fr) * 1992-04-07 1993-10-08 Paul M. Cino Induction de cellules de cal et la preparation de taxanes
WO1994020606A1 (fr) * 1993-03-05 1994-09-15 Celex Laboratories Inc. Culture de tissus vegetaux pour la production de taxol
KR950005081B1 (ko) * 1993-07-06 1995-05-18 산림청임목육종연구소 주목 종자의 씨눈 유래의 체세포배 및 체세포배성세포 혹은 그 배양배지로부터 택솔(Taxol) 및 그 유도체를 생산하는 방법
DE69435141D1 (de) 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
DE69426692T2 (de) * 1993-11-15 2001-06-21 Mitsui Chemicals Inc Methode zur herstellung von taxan-diterpen und methode zum einten von kulturzellen, die taxan-diterpen in hohen ausbeuten herstellen
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
DK0954596T3 (da) 1996-05-24 2006-05-15 Phyton Inc Foröget produktion af taxaner ved celledyrkning af Taxus-art
WO1998011135A1 (fr) * 1996-09-12 1998-03-19 Hwang Byung Doo Proteine ressemblant au taxol (talp) et procede de preparation correspondant
IL121320A (en) 1997-02-23 2000-12-06 Ibr Ltd Extracts from cells or tissue of organisms which are capable of entering dormancy for inhibition of proliferation of target cells or tissue
WO2002085337A1 (fr) 2001-04-20 2002-10-31 The University Of British Columbia Systemes d'administration de medicament micellaire pour medicaments hydrophobes
CA2307393A1 (fr) 2000-05-01 2001-11-01 The University Of British Columbia Chimiotherapie par administration d'un ginsenoside
CA2440935A1 (fr) 2001-03-13 2002-09-19 Richard Liggins Vecteurs de delivrance de medicament micellaires, leurs precurseurs et leurs utilisations
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP2390262A1 (fr) 2003-05-16 2011-11-30 Intermune, Inc. Ligands de récepteur de chimiokine synthétique et leurs procédés d'utilisation
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2006129988A1 (fr) 2005-06-03 2006-12-07 Samyang Genex Corporation Production de masse de metabolite secondaire dans une culture de cellules vegetales par le traitement de melange a base de saccharides dans un milieu
CN100393879C (zh) * 2005-12-26 2008-06-11 合肥宏源生物技术开发有限公司 电穿孔转Ri质粒诱发红豆杉发根的方法
CA2922029C (fr) 2006-03-22 2017-11-28 Medigene Ag Une combinaison d'une preparation liposomale cationique renfermant un agent antimitotique et une preparation non liposomale renfermant un agent antimitotique
ATE519511T1 (de) 2006-06-30 2011-08-15 Cook Inc Verfahren zur herstellung und modifizierung von taxan-beschichtungen für implantierbare medizinische vorrichtungen
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2310507A4 (fr) 2008-07-08 2013-03-20 David Gladstone Inst Procédés et compositions de modulation de l'angiogenèse
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (fr) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Anticorps spécifique pour cd22 et ses procédés d'utilisation
EP2916835A4 (fr) 2012-11-12 2016-07-27 Redwood Bioscience Inc Composés et procédés pour produire un conjugué
PL2956175T3 (pl) 2013-02-15 2018-05-30 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
EP2970124B1 (fr) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Modulateurs de l'aldéhyde déshydrogénase-2 mitochondriale et leurs procédés d'utilisation
WO2015081282A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
EP3107899B1 (fr) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Amides polycycliques se liant à l'aldéhyde déshydrogénase 2 mitochondriale (aldh2) et leur utilisation pour le traitement du cancer
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2017083637A1 (fr) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Oligophosphotriesters riches en guanidinium à pénétration cellulaire pour l'administration de médicament et de sonde
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3463308B1 (fr) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations d'oxyde de polyalkylène-asparaginase et leurs procédés de fabrication et d'utilisation
TW201825087A (zh) 2017-01-05 2018-07-16 杏國新藥股份有限公司 胰臟癌治療
AU2018211081A1 (en) 2017-01-18 2019-07-18 Bioatla, Inc. Chimeric antigen receptors against Axl or Ror2 and methods of use thereof
EP3388082A1 (fr) 2017-04-13 2018-10-17 Galera Labs, LLC Poly-immunothérapie anticancéreuse avec un complexe de cycle pentaaza macrocyclique
CA3090129A1 (fr) 2018-01-31 2019-08-08 Galera Labs, Llc Polytherapie anticancereuse au moyen d'un complexe de type cycle macrocyclique pentaaza et d'un agent anticancereux a base de platine
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
EP3823674A4 (fr) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. Conjugués pour administrer un agent anticancéreux à des cellules nerveuses, méthodes d'utilisation et leurs procédés de fabrication
US11529402B2 (en) 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
WO2021033779A1 (fr) * 2019-08-22 2021-02-25 北海道三井化学株式会社 Procédé de production de racine chevelue du genre taxus
CA3163805A1 (fr) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Virus de la vaccine oncolytique a variants et ses methodes d'utilisation
JP2023512196A (ja) 2020-01-29 2023-03-24 ケンジョッケティ バイオテクノロジー，インク． 抗ｍｄｒ１抗体およびその使用
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021247426A1 (fr) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anticorps anti-abcg2 et leurs utilisations
BR112023000650A2 (pt) 2020-07-14 2023-01-31 Pfizer Vírus vaccinia recombinante
CN116490522A (zh) 2020-09-02 2023-07-25 肯乔克蒂生物技术股份有限公司 抗abcc1抗体及其应用
AU2021380659A1 (en) 2020-11-13 2023-06-01 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US11299700B1 (en) 2021-02-19 2022-04-12 Acequia Biotechnology, Llc Bioreactor containers and methods of growing hairy roots using the same
WO2023114658A1 (fr) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anticorps anti-abcb1
WO2023159220A1 (fr) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anticorps anti-cd47

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5019504A (en) * 1989-03-23 1991-05-28 The United States Of America As Represented By The Secretary Of Agriculture Production of taxol or taxol-like compounds in cell culture
ATE146527T1 (de) * 1991-02-12 1997-01-15 Nippon Steel Corp Verfahren zur herstellung von taxol mittels taxusspezies-zellkultur
US5407816A (en) * 1992-02-20 1995-04-18 Phyton Catalytic, Inc. Enhanced production of taxol and taxanes by cell cultures of taxus species
WO1994020606A1 (fr) * 1993-03-05 1994-09-15 Celex Laboratories Inc. Culture de tissus vegetaux pour la production de taxol

Also Published As

Publication number Publication date
EP0642586A1 (fr) 1995-03-15
WO1993023555A1 (fr) 1993-11-25
JPH08500973A (ja) 1996-02-06
EP0642586A4 (fr) 1995-11-29
AU4242993A (en) 1993-12-13

Similar Documents

Publication Publication Date Title
CA2136213A1 (fr) Tissus de taxus cultives en tant que source de taxol, taxanes connexes et autres composes antitumoraux et antiviraux
Malik et al. Production of the anticancer drug taxol in Taxus baccata suspension cultures: a review
Fett-Neto et al. Cell culture of Taxus as a source of the antineoplastic drug taxol and related taxanes
AU672194B2 (en) Enhanced production of taxol and taxanes by cell cultures of (taxus) species
Wickremesinhe et al. Taxus callus cultures: initiation, growth optimization, characterization and taxol production
US5019504A (en) Production of taxol or taxol-like compounds in cell culture
Gibson et al. Potential of plant cell culture for taxane production
CA2194701A1 (fr) Production de taxanes dans des cultures de cellules derivees de haploides
US5527702A (en) Callus cell induction from partially submerged explant tissue in liquid medium for preparation of taxanes
US20070026506A1 (en) Method for the production of taxol and/or taxanes from cultures of hazel cells
Badi et al. New approach to improve taxol biosynthetic
Bruňáková et al. Selection of callus cultures of Taxus baccata L. as a potential source of paclitaxel production
US5871979A (en) Method for mass production of taxol by semi-continuous culture with Taxus chinensis cell culture
Majumder et al. Biotechnological approaches for the production of potential anticancer leads podophyllotoxin and paclitaxel: an overview
Sohn et al. Paclitaxel (taxol): From nutt to drug
US6248572B1 (en) Production of taxol from taxus plant cell culture adding silver nitrate
Takeya Plant tissue culture of taxoids
Wickremesinhe et al. Taxus species (yew): in vitro culture, and the production of taxol and other secondary metabolites
JP3434892B2 (ja) タキサン型ジテルペンの製造方法
JP3897267B2 (ja) タキサン型ジテルペンの製造方法
Gorzi et al. A review of the importance of Taxol production from yew (Taxus baccata L.)
Koirala et al. Biotechnological Approaches to Optimize the Production of Amaryllidaceae Alkaloids. Biomolecules 2022, 12, 893
Wickremesinhe Callus and cell suspension cultures of Taxus as a source of taxol and related taxanes
Ciddi et al. Paclitaxel (Taxol* R) from Cell and Tissue Cultures of Taxus Sp
Jaziri et al. Bioactive Taxoid Production from Natural Sources

Legal Events

Date Code Title Description
FZDE Dead